Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Public Health Rep ; 136(5): 554-561, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34139910

RESUMEN

OBJECTIVES: Federal open-data initiatives that promote increased sharing of federally collected data are important for transparency, data quality, trust, and relationships with the public and state, tribal, local, and territorial partners. These initiatives advance understanding of health conditions and diseases by providing data to researchers, scientists, and policymakers for analysis, collaboration, and use outside the Centers for Disease Control and Prevention (CDC), particularly for emerging conditions such as COVID-19, for which data needs are constantly evolving. Since the beginning of the pandemic, CDC has collected person-level, de-identified data from jurisdictions and currently has more than 8 million records. We describe how CDC designed and produces 2 de-identified public datasets from these collected data. METHODS: We included data elements based on usefulness, public request, and privacy implications; we suppressed some field values to reduce the risk of re-identification and exposure of confidential information. We created datasets and verified them for privacy and confidentiality by using data management platform analytic tools and R scripts. RESULTS: Unrestricted data are available to the public through Data.CDC.gov, and restricted data, with additional fields, are available with a data-use agreement through a private repository on GitHub.com. PRACTICE IMPLICATIONS: Enriched understanding of the available public data, the methods used to create these data, and the algorithms used to protect the privacy of de-identified people allow for improved data use. Automating data-generation procedures improves the volume and timeliness of sharing data.


Asunto(s)
COVID-19/epidemiología , Centers for Disease Control and Prevention, U.S./organización & administración , Confidencialidad/normas , Anonimización de la Información/normas , Centers for Disease Control and Prevention, U.S./normas , Humanos , Pandemias , SARS-CoV-2 , Estados Unidos/epidemiología
3.
Infect Control Hosp Epidemiol ; 37(10): 1201-11, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27418168

RESUMEN

OBJECTIVES To develop common indicators, relevant to both EU member states and the United States, that characterize and allow for meaningful comparison of antimicrobial stewardship programs among different countries and healthcare systems. DESIGN Modified Delphi process. PARTICIPANTS A multinational panel of 20 experts in antimicrobial stewardship. METHODS Potential indicators were rated on the perceived feasibility to implement and measure each indicator and clinical importance for optimizing appropriate antimicrobial prescribing. RESULTS The outcome was a set of 33 indicators developed to characterize the infrastructure and activities of hospital antimicrobial stewardship programs. Among them 17 indicators were considered essential to characterize an antimicrobial stewardship program and therefore were included in a core set of indicators. The remaining 16 indicators were considered optional indicators and included in a supplemental set. CONCLUSIONS The integration of these indicators in public health surveillance and special studies will lead to a better understanding of best practices in antimicrobial stewardship. Additionally, future studies can explore the association of hospital antimicrobial stewardship programs to antimicrobial use and resistance. Infect Control Hosp Epidemiol 2016:1-11.


Asunto(s)
Antiinfecciosos/uso terapéutico , Programas de Optimización del Uso de los Antimicrobianos , Consenso , Utilización de Medicamentos , Relaciones Interprofesionales , Antibacterianos , Programas de Optimización del Uso de los Antimicrobianos/métodos , Programas de Optimización del Uso de los Antimicrobianos/normas , Técnica Delphi , Unión Europea , Hospitales , Humanos , Encuestas y Cuestionarios , Estados Unidos
4.
MMWR Morb Mortal Wkly Rep ; 65(18): 481-2, 2016 May 13.
Artículo en Inglés | MEDLINE | ID: mdl-27171735

RESUMEN

On September 17, 2015, the Pennsylvania Department of Health (PADOH) notified CDC of a cluster of three potentially health care-associated mucormycete infections that occurred among solid organ transplant recipients during a 12-month period at hospital A. On September 18, hospital B reported that it had identified an additional transplant recipient with mucormycosis. Hospitals A and B are part of the same health care system and are connected by a pedestrian bridge. PADOH requested CDC's assistance with an on-site investigation, which started on September 22, to identify possible sources of infection and prevent additional infections.


Asunto(s)
Infección Hospitalaria/epidemiología , Brotes de Enfermedades , Mucormicosis/epidemiología , Trasplante de Órganos/efectos adversos , Receptores de Trasplantes , Adulto , Análisis por Conglomerados , Cuidados Críticos , Infección Hospitalaria/diagnóstico , Hospitales , Humanos , Mucormicosis/diagnóstico , Pennsylvania/epidemiología
5.
Vaccine ; 31(38): 4060-2, 2013 Aug 28.
Artículo en Inglés | MEDLINE | ID: mdl-23845820

RESUMEN

In a severe pandemic, rapid production and deployment of vaccines will potentially be critical in mitigating the impact on populations and essential services. We compared access to vaccines and timing of delivery relative to identification of A(H1N1)pdm09 and the geographic progression of the pandemic in the WHO European Region in order to identify gaps in provision. Information on vaccine procurement and donations was collected through a web-based survey conducted in all 53 member states of the Region. Among the 51 countries responding to the survey, the majority (84%) implemented vaccination campaigns against A(H1N1)pdm09. However, time of vaccine receipt and number of doses varied substantially across the region, with delayed access in many countries especially in those in the lowest income range. Improving access to influenza vaccines in low resource countries and solving issues of product liability should help reduce inequalities and operational challenges arising during a future public health crisis.


Asunto(s)
Disparidades en Atención de Salud/estadística & datos numéricos , Subtipo H1N1 del Virus de la Influenza A/patogenicidad , Vacunas contra la Influenza , Gripe Humana/epidemiología , Vacunación/estadística & datos numéricos , Recolección de Datos , Europa (Continente)/epidemiología , Humanos , Programas de Inmunización/organización & administración , Gripe Humana/virología
6.
N Engl J Med ; 369(17): 1598-609, 2013 Oct 24.
Artículo en Inglés | MEDLINE | ID: mdl-23252499

RESUMEN

BACKGROUND: Fungal infections are rare complications of injections for treatment of chronic pain. In September 2012, we initiated an investigation into fungal infections associated with injections of preservative-free methylprednisolone acetate that was purchased from a single compounding pharmacy. METHODS: Three lots of methylprednisolone acetate were recalled by the pharmacy; examination of unopened vials later revealed fungus. Notification of all persons potentially exposed to implicated methylprednisolone acetate was conducted by federal, state, and local public health officials and by staff at clinical facilities that administered the drug. We collected clinical data on standardized case-report forms, and we tested for the presence of fungi in isolates and specimens by examining cultures and performing polymerase-chain-reaction assays and histopathological and immunohistochemical testing. RESULTS: By October 19, 2012, more than 99% of 13,534 potentially exposed persons had been contacted. As of July 1, 2013, there were 749 reported cases of infection in 20 states, with 61 deaths (8%). Laboratory evidence of Exserohilum rostratum was present in specimens from 153 case patients (20%). Additional data were available for 728 case patients (97%); 229 of these patients (31%) had meningitis with no other documented infection. Case patients had received a median of 1 injection (range, 1 to 6) of implicated methylprednisolone acetate. The median age of the patients was 64 years (range, 15 to 97), and the median incubation period (the number of days from the last injection to the date of the first diagnosis) was 47 days (range, 0 to 249); 40 patients (5%) had a stroke. CONCLUSIONS: Analysis of data from a large, multistate outbreak of fungal infections showed substantial morbidity and mortality. The infections were associated with injection of a contaminated glucocorticoid medication from a single compounding pharmacy. Rapid public health actions included prompt recall of the implicated product, notification of exposed persons, and early outreach to clinicians.


Asunto(s)
Brotes de Enfermedades , Contaminación de Medicamentos , Glucocorticoides , Meningitis Fúngica/epidemiología , Metilprednisolona , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antifúngicos/uso terapéutico , Ascomicetos/aislamiento & purificación , Aspergillus fumigatus/aislamiento & purificación , Composición de Medicamentos , Femenino , Glucocorticoides/administración & dosificación , Humanos , Periodo de Incubación de Enfermedades Infecciosas , Inyecciones Espinales/efectos adversos , Masculino , Meningitis Fúngica/tratamiento farmacológico , Metilprednisolona/administración & dosificación , Persona de Mediana Edad , Salud Pública , Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/microbiología , Estados Unidos/epidemiología , Adulto Joven
10.
Clin Infect Dis ; 41 Suppl 4: S269-72, 2005 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-16032563

RESUMEN

Historically, infection with strains of methicillin-resistant Staphylococcus aureus (MRSA), which are usually multidrug-resistant, has been acquired by persons in hospitals, nursing homes, and other health care institutions. These infections are known as health care-associated MRSA infections. Community-associated MRSA (CA-MRSA) infection, which bears significant similarities to and differences from health care-associated MRSA infection, appears to be on the rise and has been described in several well-defined populations, such as children, incarcerated persons, Alaskan Natives, Native Americans, Pacific Islanders, sports participants, and military personnel. CA-MRSA infection has caused severe morbidity and death in otherwise healthy persons. Proven, reproducible strategies and programs for preventing the emergence and spread of CA-MRSA are lacking. Further surveillance and epidemiological and clinical studies on CA-MRSA infections are necessary for documenting the extent of the problem and for developing and evaluating effective prevention and control efforts.


Asunto(s)
Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Resistencia a la Meticilina , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus/efectos de los fármacos , Infecciones Comunitarias Adquiridas/epidemiología , Infecciones Comunitarias Adquiridas/prevención & control , Infecciones Comunitarias Adquiridas/transmisión , Humanos , Indígenas Norteamericanos , Personal Militar , Islas del Pacífico/etnología , Prisioneros , Factores de Riesgo , Deportes , Infecciones Estafilocócicas/epidemiología , Infecciones Estafilocócicas/microbiología , Infecciones Estafilocócicas/prevención & control , Estados Unidos/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA